KLRS

ElevateBio, LLC

Known title: DirectorCIK: 0001818060

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 30, 2026

Kalaris Therapeutics Moves in Pre-Market Amid Low RSI. Kalaris Therapeutics was highlighted in a roundup of health care stocks moving in Wednesday's pre-market session. The stock is currently trading near its 52-week low, with the RSI indicating oversold conditions. Analysts maintain a wide range of price targets for the company, reflecting varying views on its future performance.

this person other insiders at KLRS

Transaction History

KLRS▲ Buy$15.0M

We use analytics to understand how market-wall is used. No personal data is sold.